Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline - Richardson, Paul G.; Sonneveld, Pieter; Schuster, Michael W.; Stadtmauer, Edward A.; Facon, Thierry; Harousseau, Jean-Luc; Ben-Yehuda, Dina; Lonial, Sagar; Goldschmidt, Hartmut; Reece, Donna; Bladé, Joan; Boccadoro, Mario; et al. (British journal of haematology, 2009)
Gesehen am 14.01.2022